| Objective:To investigate the expression level of Caveolin-1and MDR1mRNA in bone marrow mononuclear cells (BMMCs) of acute myeloid leukemia (AML) patients, and analyze the correlation between Caveolin-1and MDR1mRNA expression in BMMCs of AML patients and evaluate the clinical significance of the expression levels of Caveolin-1and MDR1in AML patients.Methods:1. Total83cases of Bone marrow samples were collected from AML patients, of which included35cases of new diagnosed patients,14cases of refractory AML patients,23cases of AML patients in complete remission,11cases of patients in relapse.11cases of non-neoplastic patients were used as controls.2. BMMCs were isolated from marrow samples and then total RNA was extracted. The mRNA expression levels of Caveolin-1, MDR1and β-actin were detected by real-time quantitative PCR. The relative quantification method was used to calculate the relative expression values of Caveolin-1and MDR1. The formula2-△Ct×105was used to calculate relative gene expression values.3. The Mann-Whitney U test was adopted to analysis the mRNA expression levels of Caveolin-1and MDR1among each group. The Spearman correlation test was undertaken to research the relationship between MDR1and Caveolin-1. The correlation analysis between Caveolin-1and WBC count, percentage of bone marrow blasts were analyzed by the Spearman correlation test. P value≤0.05was considered statistically significant.Results:1. The relative expression values of Caveolin-1mRNA in new diagnosed AML patients was0.755(0.142,1.291), the remission group was0.255(0.037,0.605), the relapse group was15.290(9.577,160.167) and the refractory group is1314.312(172.620,4134.227). The relative expression value in the control group was2.057 (1.109,4.000). The Caveolin-1relative expression level in the new diagnosed group and remission group was significantly lower than the control group (P<0.01) Both the relapse group and the refractory group had a significantly higher levels of Caveolin-1expression than the control group, the new diagnosed group and the remission group (P<0.0001). There were no significantly difference in the values of Caveolin-1in new diagnosed and remission group (P>0.05)2. The relative expression values of MDR1mRNA in new diagnosed AML patients was54.555(10.039,170.377), the remission group was16.803(4.254,72.912), the relapse group was2354.253(144.471,10564.030) and the refractory group was2069.290(551.877,20870.390). The relative expression value in the control group was17.872(12.292,31.246). The relative expression value of MDR1mRNA of the new diagnosised group was higher than control group and remission group (P<0.05).There were no significantly difference of the relative expression values of MDR1mRNA among the control group and the remission group. The relative expression value of MDR1mRNA in the relapse group and the refractory group were significantly higher than that in the control group, new diagnosised group and remission group (P<0.001).3. The correlation analysis of Caveolin-1and MDR1mRNA expresison: Significantly positive correlation was found between the expression of Caveolin-1and MDR-1mRNA in the new diagnosed group (r=0.709P<0.001), the remission group(r=0.713P<0.001), the relapse group(r=0.891P<0.001)and the control group (r=0.926P<0.0001). Significantly negative correlation was found in refractory group (r=-0.833P<0.001)4. In new diagnosed group, the relative expression values of Caveolin-1and MDR1showed no significantly correlation with the percentage of blasts cells in bone marrow, the percentage of peripheral blood immature cells and the peripheral blood leukocyte count (P>0.05).Conclusion:1. Caveolin-1levels were shown significantly difference according to the different states of AML, significant lower in new diagnosed and significant higher in relapse than control group. Caveolin-1may have dual roles in AML. 2. There was no significant difference in the MDR1expression levels of the new diagnosed group and the remission group of AML and the control group; the relapse group and refractory group of AML show a significantly higher level of MDR1expression than the new diagnosed group and the remission group. These results suggest that MDR-1is involved with the relapse and drug-resistance.3. MDR1and Caveolin-1gene expressions were positive correlated significantly in the new diagnosed group, the remission group and the relapse group of AML, but the refractory group showed a negative correlation, shows that Caveolin-1plays a double role during the different stages of AML.4. Caveolin-1and MDR1expressions show no correlation with the percentage of bone marrow blast cells, the percentage of peripheral blood immature cells and the peripheral blood leukocyte count of AML. |
